Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Seront

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Frontiers in Oncology|February 9, 2026
Correction: A case report of malignant hypertension and multiorgan dysfunction during immunotherapy for gallbladder cancerCaroline Anthon, Hugo Pierret, Frederic Houssiau, et al.
Frontiers in Oncology|June 5, 2026
Case Report: Cardiac metastasis from urothelial carcinoma with predominant squamous differentiation in a young woman: first reported case treated with enfortumab vedotin plus pembrolizumabAlix Vansteeger, El Mamoune El Ghali Benlemlih, Antoine Delmarche, et al.
The Journal of Clinical Investigation|August 11, 2015
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjectsElisa Boscolo, Nisha Limaye, Lan Huang, et al.
JCI Insight|November 8, 2023
Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformationsEmmanuel Seront, An Van Damme, Catherine Legrand, et al.
Journal for Immunotherapy of Cancer|May 24, 2025
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trialJérémy Blanc, Aurélien Carnot, Philippe Barthélémy, et al.
Acta Oncologica (Stockholm, Sweden)|July 30, 2025
Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?Alexander Decruyenaere, Gennigens Christine, Rottey Sylvie, et al.
BMC Cancer|December 3, 2021
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)Nieves Martinez Chanza, Louisa Soukane, Philippe Barthelemy, et al.
Clinical Genitourinary Cancer|December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 StudyFernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
The Oncologist|December 2, 2016
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based TherapyJean-Pascal Machiels, Aline Van Maanen, Jean-Marie Vandenbulcke, et al.
Clinical & Experimental Metastasis|September 6, 2025
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 datasetAlessandro Rizzo, Anas Zayed, Elsa Vitale, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Frontiers in Oncology|February 9, 2026
Correction: A case report of malignant hypertension and multiorgan dysfunction during immunotherapy for gallbladder cancerCaroline Anthon, Hugo Pierret, Frederic Houssiau, et al.
Frontiers in Oncology|June 5, 2026
Case Report: Cardiac metastasis from urothelial carcinoma with predominant squamous differentiation in a young woman: first reported case treated with enfortumab vedotin plus pembrolizumabAlix Vansteeger, El Mamoune El Ghali Benlemlih, Antoine Delmarche, et al.
The Journal of Clinical Investigation|August 11, 2015
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjectsElisa Boscolo, Nisha Limaye, Lan Huang, et al.
JCI Insight|November 8, 2023
Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformationsEmmanuel Seront, An Van Damme, Catherine Legrand, et al.
Journal for Immunotherapy of Cancer|May 24, 2025
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trialJérémy Blanc, Aurélien Carnot, Philippe Barthélémy, et al.
Acta Oncologica (Stockholm, Sweden)|July 30, 2025
Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?Alexander Decruyenaere, Gennigens Christine, Rottey Sylvie, et al.
BMC Cancer|December 3, 2021
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)Nieves Martinez Chanza, Louisa Soukane, Philippe Barthelemy, et al.
Clinical Genitourinary Cancer|December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 StudyFernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
The Oncologist|December 2, 2016
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based TherapyJean-Pascal Machiels, Aline Van Maanen, Jean-Marie Vandenbulcke, et al.
Clinical & Experimental Metastasis|September 6, 2025
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 datasetAlessandro Rizzo, Anas Zayed, Elsa Vitale, et al.
Pageof 8